Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 150Lung Neoplasms 58Pancreatic Neoplasms 34Neoplasms 20Neoplasm Metastasis 15Breast Neoplasms 15Adenocarcinoma of Lung 15Brain Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 13Glioblastoma 12Non-Squamous Non-Small Cell Lung Cancer 11Head and Neck Neoplasms 11Gliosarcoma 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Hepatocellular 10Colorectal Neoplasms 8Carcinoma, Renal Cell 8Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Gallbladder Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 4Kidney Neoplasms 4Fallopian Tube Neoplasms 4

Interventions

Filgrastim 3Cyclophosphamide 3sargramostim 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Irinotecan 2Etoposide 2Erlotinib Hydrochloride 2Cisplatin 2Carboplatin 2phenylacetic acid 1palbociclib 1olaparib 1erdafitinib 1becatecarin 1aldesleukin 1X-Rays 1Vinorelbine 1Topotecan 1Thiotepa 1Tamoxifen 1Sunitinib 1Specimen Handling 1Radiotherapy 1RMP 7 1Phantoms, Imaging 1Paclitaxel 1Nuclear Medicine Department, Hospital 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Familial ependymoma × Erlotinib Hydrochloride × Clear all
NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated
25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT01247922 2024-12-06

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Astellas Pharma Inc

Phase 2 Terminated
4 enrolled 9 charts

Familial ependymoma, Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡